证券代码：603368 证券简称：柳药集团 公告编号：2026-007 一、担保情况概述 （一）担保的基本情况 2026 年 1 月，为支持广西柳药集团股份有限公司（以下简称"公司"）下属 控股子公司的生产经营和业务发展需要，公司就下属控股子公司向银行申请综合 授信等事项合计新增 20,000 万元的担保，同时解除担保金额合计 24,722.33 万元。 2026 年 1 月，公司为下属控股子公司提供担保的具体情况如下： 广西柳药集团股份有限公司 关于为下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 大药房"） | | 广西桂中大药房连锁有限责任公司（简称"桂中 | | --- | --- | --- | --- | --- | | 担保 | 本次担保金额 | 20,000.00 | 万元 | | | 对象 | 实际为其提供的担保余额 | 48,000.00 | 万元（含本次） | | | | 是否在前期预计额度内 | 是 | □ ...

Group 1 - The company has approved a share repurchase plan using its own and self-raised funds, with a total repurchase amount between RMB 100 million and RMB 200 million, and a maximum repurchase price of RMB 25.70 per share [1] - The repurchase period is set for up to 12 months from the board's approval date [1] - The company has repurchased 10.803 million shares, representing 2.72% of the total share capital, with a total expenditure of RMB 198.6382 million as of January 31, 2026 [2] Group 2 - The highest repurchase price recorded was RMB 19.07 per share, while the lowest was RMB 17.83 per share [2] - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [3]

Group 1 - The core announcement is that Liu Pharmaceutical Group (603368) has repurchased a total of 10.803 million shares through centralized bidding, which represents 2.72% of the company's current total share capital [1]

Group 1 - The core point of the article is that Liu Pharmaceutical Group (603368.SH) has announced a share buyback program, with a total of 10.803 million shares repurchased, representing 2.72% of the company's total share capital as of January 31, 2026 [1] - The highest price for the repurchased shares was 19.07 yuan per share, while the lowest price was 17.83 yuan per share [1] - The total amount paid for the repurchase, excluding transaction fees, was 199 million yuan [1]

Group 1 - The company, Liu Pharmaceutical Group (603368.SH), announced a share buyback program, with a total of 10.803 million shares repurchased as of January 31, 2026, representing 2.72% of the company's total share capital [1] - The highest price for the repurchased shares was 19.07 CNY per share, while the lowest price was 17.83 CNY per share [1] - The total amount paid for the repurchase, excluding transaction fees, was 199 million CNY [1]

证券代码：603368 证券简称：柳药集团 公告编号：2026-006 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 7 月 7 | 25 | 日~2026 | 年 | 月 | 24 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 1,080.30万股 | | | | | | | 累计已回购股数占总股本比例 | 2.72% | | | | | | | 累计已回购金额 | 19,863.82万元 | | | | | ...

Group 1 - The core point of the news is that Guangxi Liuyuan Group Co., Ltd. won a procurement project from the Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital, with a bid amount of 4.76 million yuan [1][2] Group 2 - In 2024, the company's operating revenue was 21.182 billion yuan, with a growth rate of 1.78% [2] - The net profit attributable to the parent company for 2024 was 855 million yuan, with a growth rate of 0.62% [2] - The return on equity was 11.62% [2] - In the first half of 2025, the company's operating revenue was 10.301 billion yuan, with a decline of 3.21% [2] - The net profit attributable to the parent company for the first half of 2025 was 429 million yuan, with a decline of 7.52% [2] Group 3 - The company operates in the daily consumer industry, with main product types including biological diagnostic reagents, organic chemical pesticides, diagnostic treatment equipment, and traditional Chinese medicine pieces [2] - The main business composition in 2024 was: pharmaceuticals 85.41%, medical devices 13.45%, others 0.74%, and other businesses 0.4% [2]

Group 1 - On January 23, Liuyao Group's stock increased by 1.57%, with a trading volume of 275 million yuan [1] - The financing data shows that on the same day, Liuyao Group had a financing purchase amount of 28.11 million yuan and a financing repayment of 44.46 million yuan, resulting in a net financing outflow of 16.35 million yuan [1] - As of January 23, the total balance of margin trading for Liuyao Group was 451 million yuan, which accounts for 6.07% of its circulating market value, indicating a low level compared to the past year [1] Group 2 - As of September 30, Liuyao Group had 30,400 shareholders, a decrease of 7.62% from the previous period, while the average circulating shares per person increased by 8.25% to 13,050 shares [2] - For the period from January to September 2025, Liuyao Group reported an operating income of 15.758 billion yuan, a year-on-year decrease of 1.47%, and a net profit attributable to shareholders of 646 million yuan, down 9.81% year-on-year [2] - Since its A-share listing, Liuyao Group has distributed a total of 1.789 billion yuan in dividends, with 720 million yuan distributed over the past three years [2]

Core Viewpoint - The announcement details the maturity and repayment results of the "Liuyao Convertible Bonds," including conversion statistics and the impact on the company's financial structure [1][3][4]. Group 1: Issuance and Maturity Overview - The company issued 8,022,000 convertible bonds with a total value of 800.22 million yuan, with a maturity period from January 16, 2020, to January 15, 2026 [2]. - The bonds were listed on the Shanghai Stock Exchange starting February 24, 2020, under the name "Liuyao Convertible Bonds" and code "113563" [2]. Group 2: Conversion and Repayment Details - As of January 15, 2026, a total of 1,222,000 yuan worth of bonds were converted into 55,677 shares, representing 0.0154% of the total shares before conversion [3]. - The total number of bonds due for repayment is 8,009,780, with a total repayment amount of 865,056,240 yuan, scheduled for January 16, 2026 [4][5]. Group 3: Financial Impact and Share Capital Changes - The conversion of bonds increased the company's total share capital by 55,677 shares, which may dilute earnings per share in the short term but will not affect governance or ongoing operations [6][7]. - The company maintains a healthy financial status and normal cash flow, indicating that the bond repayment will not impact daily operations [6][7]. Group 4: Taxation Policy for Non-Resident Enterprises - From January 1, 2026, to December 31, 2027, interest income from bonds held by foreign institutions will be temporarily exempt from corporate income tax and value-added tax, benefiting non-resident enterprises [8].

| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2026-005 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于"柳药转债"到期兑付结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 到期兑付总金额：865,056,240.00 元 ● 兑付资金发放日：2026 年 1 月 16 日 ● 可转债摘牌日：2026 年 1 月 16 日 次提示性公告》（公告编号：2025-097、2025-099、2025-100），并于 2026 年 1 月 8 日披露了《关于"柳药转债"到期兑付暨摘牌的公告》（公告编号：2026-003），公 告具体内容详见上海证券交易所网站（www.sse.com.cn）。相关兑付事项如下： 1、兑付登记日：2026 年 1 月 15 日 2、兑付对象：截至 2026 年 1 月 15 日上海证券交易所收市后在中国证券登记 结算有限责任公司上海分公司（以下简称 ...